Table 2.

Subgroup Analyses

Population		TC	LDL‐C	Non–HDL‐C	ApoB	hs‐CRP
Hypercholesterolemic	MD, %	−7.9	−13.1	−9.0	−7.1	−9.0
	95% CI, %	−12.9 to −3.0	−23.8 to −2.4	−16.3 to −1.7	−11.3 to −2.9	−16.3 to −1.7
	P value	0.002	0.016	0.016	0.001	0.016
Statin intolerant	MD, %	−16.0	−23.4	−20.6	−16.4	−19.7
	95% CI, %	−20.3 to −11.7	−30.1 to −16.7	−28.6 to −12.5	−21.8 to −10.9	−25.2 to −14.3
	P value	<0.001	<0.001	<0.001	<0.001	<0.001
High cardiovascular risk	MD, %	−11.0	−19.0	−13.1	−11.1	−13.2
	95% CI, %	−12.1 to −9.8	−21.7 to −16.4	−14.6 to −11.6	−12.5 to −9.7	−14.8 to −11.7
	P value	<0.001	<0.001	<0.001	<0.001	<0.001

Changes in TC, LDL‐C, non–HDL‐C, ApoB, and hs‐CRP after 12 weeks of treatment with bempedoic acid compared with control treatment group, separately analyzing patients with high cardiovascular risk, statin‐intolerant patients, and patients with hypercholesterolemia on maximally tolerated statin therapy.

ApoB indicates apolipoprotein B; HDL‐C, high‐density lipoprotein cholesterol; hs‐CRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; MD, mean difference; and TC, total cholesterol.